Methodology

All entries for: Santo Therapeutics Co.

March 10, 2026

Santo Therapeutics Co.

Orphan Drug Designation

treatment of NF2-related schwannomatosis (formerly NF2)

Disease Area: Rare Disease
Source
Scroll to Top